6533b7d3fe1ef96bd1260114

RESEARCH PRODUCT

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin

Andrés MoyaNuria Jiménez-hernándezFernando González-candelasFernando CarnicerInmaculada García-roblesMaría Alma BrachoJuan A. Del OlmoEnrique OrtegaJosé M. CuevasManuela Torres-puenteBoris Wrobel

subject

Genome evolutionHepatitis C virusEvolutionary Biology/Bioinformaticslcsh:MedicineAlpha interferonGenome ViralHepacivirusBiologyVirology/Immune EvasionInterferon alpha-2Viral Nonstructural Proteinsmedicine.disease_causeGenomeAntiviral AgentsEvolution Molecularchemistry.chemical_compoundGenetics and Genomics/Population GeneticsRibavirinmedicineHumanslcsh:ScienceNS5APhylogenyGenetics:CIENCIAS DE LA VIDA::Genética ::Otras [UNESCO]Virology/Antivirals including Modes of Action and ResistanceMultidisciplinaryEvolutionary Biology/Evolutionary and Comparative GeneticsHepatitis C virusRibavirinlcsh:RGenetic VariationInterferon-alphaVirologyComplementarity Determining RegionsHepatitis CVirology/Virus Evolution and SymbiosisRecombinant ProteinsUNESCO::CIENCIAS DE LA VIDA::Genética ::OtrasHypervariable regionchemistryViral evolutionInterferonlcsh:QGenetic variabilityHepatitis C virus; Genetic variability; Interferon; Ribavirin; Combined therapyCombined therapyResearch Article

description

We present an analysis of the selective forces acting on two hepatitis C virus genome regions previously postulated to be involved in the viral response to combined antiviral therapy. One includes the three hypervariable regions in the envelope E2 glycoprotein, and the other encompasses the PKR binding domain and the V3 domain in the NS5A region. We used a cohort of 22 non-responder patients to combined therapy (interferon alpha-2a plus ribavirin) for which samples were obtained before initiation of therapy and after 6 or/and 12 months of treatment. A range of 25-100 clones per patient, genome region and time sample were sequenced. These were used to detect general patterns of adaptation, to identify particular adaptation mechanisms and to analyze the patterns of evolutionary change in both genome regions. These analyses failed to detect a common adaptive mechanism for the lack of response to antiviral treatment in these patients. On the contrary, a wide range of situations were observed, from patients showing no positively selected sites to others with many, and with completely different topologies in the reconstructed phylogenetic trees. Altogether, these results suggest that viral strategies to evade selection pressure from the immune system and antiviral therapies do not result from a single mechanism and they are likely based on a range of different alternatives, in which several different changes, or their combination, along the HCV genome confer viruses the ability to overcome strong selective pressures. cuevast@uv.es; mtorresp@uv.es; njimenez@uv.es; bracho@uv.es; garciai@uv.es; wrobel@uv.es; moya@uv.es; gonzalef@uv.es

10.1371/journal.pone.0003058http://europepmc.org/articles/PMC2518109